Hemophilia Ontario has submitted a formal letter to provincial health decision‑makers in alignment with the recent efforts of the Canadian Hemophilia Society, asking the province to accept the Canadian Blood Services recommendation to add Altuviiio (efanesoctocog alfa) to the formulary for the treatment of hemophilia A. This new ultra‑long‑acting factor VIII therapy has the potential to significantly improve bleed protection, reduce treatment burden, and support better long‑term joint health for many in our community.
Our advocacy aligns with the recent efforts of the Canadian Hemophilia Society (CHS), which has called on provinces and territories to accept the Canadian Blood Services (CBS) recommendation to add Altuviiio to the national formulary. In its December update, the CHS emphasized the strong clinical evidence supporting Altuviiio and the meaningful benefits it may offer to individuals with hemophilia A across a range of needs—from breakthrough bleeds to chronic joint disease to pediatric care .
As a provincial organization, Hemophilia Ontario is committed to ensuring that people in our community have equitable access to the safest and most effective therapies available. Our letter reinforces the importance of timely decision‑making so that individuals and families in Ontario are not left waiting for treatments already recognized as beneficial by national experts and regulatory bodies.
We will continue to monitor the provincial review process and share updates as they become available. Advocacy is strongest when our community is informed and engaged, and we are grateful to everyone who continues to raise their voice in support of improved care and choice for people with bleeding disorders.
